Blood-Borne Diseases

Prequalification status indicates that the vaccine meets the WHO’s standard for efficacy, safety, and quality.

Since 2014 NYC Health + Hospitals has worked to maintain preparedness against diseases like Ebola.

Blood sample testing in African countries using rapid tests is a mixed message. Accuracy in HIV improved, but accuracy in hepatitis B and C testing did not.

Results from a study at a Cincinnati hospital point to the importance of testing at-risk infants for HCV as the opioid crisis impacts prevalence of the infection.

Leaders from the WHO and various impacted countries met to assess the risks of the Ebola outbreak in the Democratic Republic of the Congo and the future of the outbreak response.

Scientists from the National Institutes of Health are hopeful that diluting a dose of the VSV vaccine could be efficacious and stretch vaccine supplies even further.

Although the overall mortality rate for HCV has declined, clinicians will have to focus on individuated factors to address lingering barriers.

A patient was evaluated for Ebola in a Swedish hospital. Here's what we should take away from it.

One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.

The phase 1/2 trial of a prime-boost vaccine to prevent chronic HCV infection was completed in an at-risk population of in people who inject drugs.

The analysis of the survey responses found a statistically significant association in denial of the biomedical discourse and dissatisfaction or mistrust of the Ebola response as indicators of social resistance.

In part 2 of our Q&A with Fair, we talk about the challenges ahead in the fight against Ebola in the Democratic Republic of the Congo.

The FDA has approved treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to 8 weeks.

In part 1 of our Q&A with Fair, we talk about his background, education, and experience, and also how the outbreak response to the current Ebola outbreak in the DRC differs from traditional disaster response.

In this outbreak, 18% of Ebola cases have been tied to health care transmission. How can we prevent this from continuing?

The target action date for the V920 investigational Ebola vaccine is set for March 14, 2020.

Although drinking water-associated outbreaks are rarely reported in the United States, they were the most commonly reported etiology for outbreaks associated with untreated ground water from 1971-2008.

Investigators observed that, when compared with the general population of Guinea, survivors of Ebola had a 5-fold increased risk of mortality over a mean of 1 year of follow-up after discharge.

As the summer comes to a close, our editorial team is looking back at the top FDA approvals of 2019 to date and looking ahead at what is left on the docket this year.

No one knows exactly why thousands of patients in dozens of states have contracted hepatitis A in recent years. In the absence of an explanation, public health officials are focusing on vaccination.

The Biomedical Advanced Research and Development Authority will contribute $23 million for Merck to continue manufacturing the Ebola vaccine over the next year.

A team of investigators review global HCV infection rates in an attempt to quantify HCV-associated cardiovascular disease.

The first Contagion® Connect podcast features a conversation with Dr. Alexandra Phelan about the impact of pandemic bonds in the ongoing Ebola outbreak in the DRC.

Variances in collection and siloed efforts are hurting this outbreak response.

The research team deciphered that the nitazoxanide boosts the ability of specific viral sensors to detect Ebola when infected, which then sparks an antiviral immune response.